PARP Inhibitor Tested in mCRPC

Ariela Katz
Published: Friday, Nov 17, 2017
Charles J. Ryan, MD
Charles J. Ryan, MD
Rucaparib (Rubraca), a drug approved for the treatment of ovarian cancer, might also be used to treat patients with metastatic castration-resistant prostate cancer (mCRPC), pending the results of a phase III study.

-mutated population, and this will potentially highlight some of the overlap between hormone sensitivity and DNA repair alterations.”

Trial Details

The trial is designed to test the efficacy of rucaparib in patients who have received either abiraterone or enzalutamide as initial treatment for mCRPC, but have not received chemotherapy. Eligible patients will also have a deleterious mutation in the BRCA1, BRCA2, or ATM genes.

 

Figure. Rucaparib in Patients With mCRPC and DNA Repair Mutations

Figure. Rucaparib in Patients With mCRPC and DNA Repair Mutations
According to Ryan, the main adverse events (AEs) the investigators expect to see with rucaparib are common to PARP inhibitors, and are primarily hematologic, including anemia. Other AEs observed in past trials of PARP inhibitors include fatigue, leukopenia, thrombocytopenia, and neutropenia.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x